Robert A. Figlin, MD, on RCC: Results From the ADAPT Trial

2017 ESMO Congress
Tweet this page

Robert A. Figlin, MD, of Cedars-Sinai Medical Center, discusses an interim analysis of phase III findings on rocapuldencel-T, an individualized immunotherapy, for newly diagnosed patients with metastatic renal cell carcinoma (Abstract 1137O).

Advertisement

Advertisement



Advertisement